Moomoo AI 已提取核心信息
On December 31, 2023, Ariel Gordon filed an amendment to Schedule 13G/A with the United States Securities and Exchange Commission, disclosing a 6.9% ownership stake in NeuroSense Therapeutics Ltd., which includes warrants to purchase 25,954 ordinary shares. The filing indicates that Gordon now beneficially owns 1,060,561 shares in the biotechnology company, based on 15,379,042 ordinary shares outstanding as provided by NeuroSense Therapeutics. The address for NeuroSense Therapeutics' principal executive offices is listed as 11 Hamenofim Street, Herzliya, Israel. Ariel Gordon, who holds both Israeli and U.S. citizenship, has sole voting and dispositive power over the shares. The filing was completed on February 13, 2024, and asserts that the acquisition of the shares is not for the purpose of changing or influencing the control of the issuer, nor is it in connection with any transaction having that purpose or effect.
On December 31, 2023, Ariel Gordon filed an amendment to Schedule 13G/A with the United States Securities and Exchange Commission, disclosing a 6.9% ownership stake in NeuroSense Therapeutics Ltd., which includes warrants to purchase 25,954 ordinary shares. The filing indicates that Gordon now beneficially owns 1,060,561 shares in the biotechnology company, based on 15,379,042 ordinary shares outstanding as provided by NeuroSense Therapeutics. The address for NeuroSense Therapeutics' principal executive offices is listed as 11 Hamenofim Street, Herzliya, Israel. Ariel Gordon, who holds both Israeli and U.S. citizenship, has sole voting and dispositive power over the shares. The filing was completed on February 13, 2024, and asserts that the acquisition of the shares is not for the purpose of changing or influencing the control of the issuer, nor is it in connection with any transaction having that purpose or effect.
2023年12月31日，爱丽儿·戈登向美国证券交易委员会提交了附表13G/A的修正案，披露了NeuroSense Therapeutics Ltd. 6.9％的所有权，其中包括购买25,954股普通股的认股权证。该文件显示，根据NeuroSense Therapeutics提供的15,379,042股已发行普通股，戈登现在实益拥有这家生物技术公司的1,060,561股股份。NeuroSense Therapeutics主要行政办公室的地址列为以色列赫兹利亚哈梅诺菲姆街11号。拥有以色列和美国国籍的爱丽尔·戈登对股票拥有唯一的投票权和处置权。该文件于2024年2月13日完成，并断言收购这些股份的目的不是为了改变或影响发行人的控制权，也与任何具有该目的或效力的交易有关。
2023年12月31日，爱丽儿·戈登向美国证券交易委员会提交了附表13G/A的修正案，披露了NeuroSense Therapeutics Ltd. 6.9％的所有权，其中包括购买25,954股普通股的认股权证。该文件显示，根据NeuroSense Therapeutics提供的15,379,042股已发行普通股，戈登现在实益拥有这家生物技术公司的1,060,561股股份。NeuroSense Therapeutics主要行政办公室的地址列为以色列赫兹利亚哈梅诺菲姆街11号。拥有以色列和美国国籍的爱丽尔·戈登对股票拥有唯一的投票权和处置权。该文件于2024年2月13日完成，并断言收购这些股份的目的不是为了改变或影响发行人的控制权，也与任何具有该目的或效力的交易有关。
有用
没用